{"url_path":"/sec/sgmt/8-k/2026-06-12/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-073431-index.html","accession_number":"0001104659-26-073431","cik":"0001400118","ticker":"SGMT","issuer_name":"Sagimet Biosciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1400118/0001104659-26-073431-index.html","primary_entity_key":"0001400118","primary_entity_name":"Sagimet Biosciences Inc."},"word_count":290,"has_tables":true,"body_markdown":"**Item 5.07**\n**Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn June 12, 2026, the Company held its 2026 Annual Meeting of\nStockholders (the “Annual Meeting”). As of April 17, 2026, the record date for the Annual Meeting, there were 32,017,613\noutstanding shares of the Company’s Series A common stock. The Annual Meeting was conducted virtually, and the following is\na brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting,\nwhich are described in detail in the Company’s definitive proxy statement for the Annual Meeting, filed with the U.S. Securities\nand Exchange Commission on April 21, 2026.\n\n \n\n(a) *Proposal 1 - Election of Class III Directors*.\nEach of Jennifer Jarrett, Anne Phillips, M.D., David Happel and George Kemble, Ph.D. were elected to the Board to serve as Class III\ndirectors until the 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier\ndeath, resignation, retirement, disqualification or removal, as follows:\n\n \n\nName \nFor \nWithheld \nBroker Non-Votes\n\nJennifer Jarrett \n6,461,429 \n2,555,268 \n10,124,106\n\nAnne Phillips, M.D. \n7,806,504 \n1,210,193 \n10,124,106\n\nDavid Happel \n8,753,884 \n262,813 \n10,124,106\n\nGeorge Kemble, Ph.D. \n8,688,684 \n328,013 \n10,124,106\n\n \n\n(b) *Proposal 2 - Ratification of Independent Registered Public\nAccountant*. The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year\nwas ratified, as follows:\n\n \n\nFor \nAgainst \nAbstentions \nBroker Non-Votes\n\n19,091,619 \n13,960 \n35,224 \n0\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nas amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \nSagimet Biosciences Inc.\n\n \n \n \n\nDate: June 12, 2026\nBy:\n/s/ David Happel\n\n \n \nDavid Happel\n\n \n \nChief Executive Officer"}